Background and methods: Portal vein thrombosis (PVT) has been reported as a complication of IBD in some case reports. We describe the presentation, diagnostic approaches, underlying risks factors and clinical outcome of 8 IBD patients with PVT. Case-series: The patients presented with partial PVT (4 patients) or portal cavernoma. Five patients had undergone surgery. In 2 patients portal biliopathy was diagnosed after detection of PVT. In 4 patients, the diagnosis of PVT was made while IBD was in remission. Five patients showed at least one risk factor for hypercoagulability: lupus anti-coagulant (one patient), increased von Willebrand factor (2 patients) or homocysteine levels (4 patients). Four patients received anticoagulant therapy for 6 months. None experienced other thrombotic events during a median of 5 years (range 2-8 years). Conclusion: PVT is a potential complication of IBD, usually associated with acquired or inherited risks factors for hypercoagulability and with a benign outcome.
Introduction
Portal vein thrombosis (PVT) is a form of venous thrombosis affecting the portal vein, which can lead to portal hypertension and reduction in the blood supply to the liver. Portal vein thrombosis is frequent in advanced cirrhosis, in particular when associated with hepatocellular carcinoma. However, it is relatively rare in a previously healthy subject where hypercoagulability, due to inherited or acquired conditions, and clonal disorders such as the Philadelphia chromosome-negative chronic myeloproliferative disorders or abdominal sepsis, are the principal causes. 1 Inflammatory bowel diseases (IBD) are chronic abdominal inflammatory conditions with a potential hypercoagulable state and characterized by an incidence of systemic thromboembolic events higher than in the general population.
The acute episode may be asymptomatic or characterized by nonspecific symptoms and the diagnosis is often difficult to achieve, in particular when symptoms overlap with those of precipitating causes, such as acute abdominal infection. Thus, this condition is frequently recognized at the chronic stage because of complications of portal hypertension. At the chronic stage ultrasound can reveal the portal cavernoma, a hepatopetal network of collaterals around the obstructed portal tract. The cavernous transformation of the portal vein occurs when the native portal vein is thrombosed and myriads of collateral channels develop in the porta hepatis to bypass the occlusion.
Spontaneous mesenteric and portal vein thrombosis as a complication of IBD has already been reported in some case reports and in small series showing that the prevalence of this condition ranges from 0.1 to 1%, and has been described as a deadly condition. However, recent series show that it may also be a symptom-free complication occurring in a perioperative setting and in patients with a hypercoagulability state. 2, [5] [6] [7] [8] [9] [10] We reviewed the records from our IBD center to identify patients who developed PVT during their clinical course. We described their clinical presentation, underlying risk factors, diagnostic methods and clinical outcome.
Case series
A retrospective chart review of patients followed in our IBD center was performed to identify individuals who had had PVT during their lifetime. In particular, patients were identified from the computerized databases of IBD and ultrasound units of Gastroenterology of L. Sacco University Hospital, by searching "portal thrombosis or portal cavernoma" in database reports, from January 1997 to June 2010.
All data, and charts and discharge reports of identified patients were then reviewed to acquire details about clinical presentation, diagnostic modalities used and outcome.
In particular, smoking and contraceptive use, previous surgery and clinical conditions, namely clinical disease activity, at the time of diagnosis of PVT were investigated. Hypercoagulability tests performed just after the diagnosis of PVT were retrieved. Evaluation for hypercoagulability included: anti-thrombin, protein C and S activity, plasma homocysteine level, PT, aPTT and antiphospholipid antibody testing, including ELISA assay for the anticardiolipin antibodies (IgG and IgM) and lupus anticoagulant testing. Testing for Factor V Leiden, prothrombin, and methyltetrahydrofolate reductase (MTHFR) mutations were also considered.
We indentified 8 patients (5 males; mean age 47.3 ± 10.4) with PVT or portal cavernoma (Fig. 1 ) that accounted for a prevalence of 0.17%, considering the total of IBD patients regularly followed in our Unit until now (4573 patients) ( Table 1) . Six had Crohn's disease (CD) and two had ulcerative colitis (UC). All CD patients had ileal disease (one ilecolic disease) and 4 had a past history of surgery for strictures. All UC patients had a pancolitis and 1 had undergone colectomy 3 months earlier.
Mean time from diagnosis of IBD to the detection of PVT was 14.8 ± 6.6 years. In 4 patients the diagnosis of PVT was made while their IBD was in clinical remission, while 4 patients (2 UC patients and 2 CD patients) had an active disease. There were no severe presentations or specific manifestations leading to diagnosis of PVT, which was made by ultrasound and color Doppler ultrasound in all patients (6 confirmed by CT).
At least one underlying risk factor for hypercoagulability was identified in 5 patients. Lupus anticoagulant was detected in one patient, while 2 patients had elevated von Willebrand factor levels and 4 patients increased homocysteine levels. In addition, 4 patients had the mutation 677 of MTHFR reductase (3 heterozygotes and 1 homozygote). No other thrombophilic risk factors were found. In particular, protein C or S activity, PT, a PTT and antithrombin were normal in all patients. No patients showed anticardiolipin antibodies, Factor V Leiden or prothrombin mutation. Three patients were active cigarette smokers. No patients were taking oral contraceptives, or had had thrombosis in other sites prior to PVT. One patient had HBV-positive chronic hepatitis that was already known prior the diagnosis of PVT. In 2 other patients portal biliopathy, complicated by gastroesophageal varices, was diagnosed just after PVT detection. The past history of these patients was negative regarding liver diseases.
Three patients with partial PV thrombosis and one with portal cavernoma received anticoagulant treatment for at least 6 months. All patients underwent ultrasonographic and color Doppler follow-up showing the resolution of partial PV or branch thrombosis in 3 patients (spontaneously in patient #3 and following anticoagulation in patients #5 and #6) and the stable behavior of all portal cavernomas and of a partial PV and branch thrombosis (patient #2). No patient needed further long-term anticoagulant treatment and none experienced other thrombotic events during a median follow-up of 5 years (range: 2-8 years).
Discussion
Portal vein thrombosis is a relatively rare condition, mainly caused by advanced cirrhosis and, to a lesser degree, myeloproliferative disorders, abdominal sepsis and IBD. 1 We identified 8 patients with PVT that accounted for a prevalence of 0.17%, considering the total of IBD patients followed in our Unit during the study period (4573 patients). This prevalence is higher than that reported by Hatoum et al. 5 but is in keeping with that of Talbot et al. 2 However, it is difficult to give the exact prevalence of PVT because it was not associated with specific symptoms. This observation concurs with data of other retrospective series, 2, 6 showing that most IBD patients developed portal or mesenteric vein thrombosis while clinically asymptomatic at the time of diagnosis. 2, 6 For these reasons, as in the other studies, it was impossible to ascertain the exact time at which thrombosis developed in most subjects.
Undoubtedly, the use of abdominal ultrasound, that is frequently employed to assess the bowel and upper abdomen in the management of IBD patients in our practice, 11, 12 allowed us to detect PVT in most asymptomatic patients. On the other hand, the accuracy of ultrasound coupled with color Doppler, as a screening test for assessing PVT has been well known for long time. 13, 14 As far as the presence of clinical risk factors for PVT is concerned, although we do not know the exact time of PVT and we do not have information about the risk factors at that time, we identified ileal or colonic resection in 5 patients and concomitant hepatic diseases in 3 out 7 patients. Previous abdominal surgery in IBD patients, and in particular, the perioperative period and restorative proctocolectomy have been already suggested as relevant risk factors for development of deep vein thrombosis, and mesenteric or portal vein thrombosis. 5, [15] [16] [17] [18] However, none of our patients had a recent surgery.
A concomitant hepatic disease (chronic hepatitis from HBV infection) was present prior to the detection of PVT in one patient. The possibility of PVT in patients with HBVhepatitis 19 has been already reported. However, 2 other patients presented clinical and biochemical features initially suggestive of primary sclerosing cholangitis after the diagnosis of PVT but this diagnosis was subsequently modified to portal biliopathy, namely the consequence of their portal cavernoma and portal hypertension. 20, 21 Other clinical causes for PVT were not found, thus confirming that PVT in IBD is likely a multivariate process with multiple potential risk factors, still largely unknown.
We also assessed the potential role of hypercoagulability as a cause for PVT. At least one inherited biochemical marker of hypercoagulability was identified in 5 patients: lupus anticoagulant was detected in one patient, while 2 patients had elevated von Willebrand factor levels and 4 patients increased homocysteine levels. The latter finding may be a marker of hypercoagulability linked to endothelial damage rather than the cause of thrombotic events. In addition, 4 patients had the mutation 677 of MTHFR reductase (3 heterozygotes and 1 homozygote). Even if the coexistence of these hemostatic abnormalities has been found in IBD patients, their presence in patients with PVT is infrequently reported (Table 2 ) and their significance is not fully understood.
Four patients received anticoagulant treatment. The reason for that only some patient was treated with anticoagulant therapy is unknown. The role of anticoagulation therapy and the mode of its administration are not well defined. On this regard the National Library of Medicine was searched (1991-2011) for articles on PVT treatment in IBD, providing information on treatment and outcome of PVT. One retrospective study of postoperative IBD patients, 4 small case-series and 19 single case-reports, including a total of 74 patients, were evaluated (Table 2) . Anticoagulation therapy with heparin and/or oral warfarin derivatives for PVT was reported in most cases (16 patients treated with heparin or low molecular weight heparin, 31 with oral anticoagulation), thrombolysis was adopted in 7 patients, but a number of patients did not receive specific therapy. 17, 30 A favorable outcome was reported in all patients, with portal recanalization in most cases.
In conclusion, our series shows that PVT may be a complication of IBD, usually associated with acquired or inherited risks factors for hypercoagulability. Despite in some patients PVT presented with portal biliopathy and oesophageal varices, this condition shows a benign and stable outcome in most cases, and does not need long term anticoagulant treatment.
